Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Danish Headache Center
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05889455CT.gov Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Without Aura
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sildenafil (this asset) | Danish Headache Center | N/A | D · 30 |
| Topiramate | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | P4 | BBB |
| DHE | Satsuma Pharmaceuticals, Inc. | P3 | BBB |
| Apsolol | Norwegian University of Science and Technology | P3 | BB |
| Rimegepant | University of South Florida | P4 | BB |
| Metoclopramide | Assistance Publique - Hôpitaux de Paris | P4 | BB |
| Dexketoprofen | Kecioren Education and Training Hospital | P4 | BB |
| Almotriptan | Messoud Ashina, MD | P4 | BB |
| Ibuprofen | Kecioren Education and Training Hospital | P4 | BB |
+42 more in the Migraine Without Aura cohort
Other indications for Sildenafil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pulmonary Hypertension | — | P4 | BB · 71 |
| Sickle Cell Disease | — | P4 | BB · 68 |
| Erectile Dysfunction | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sildenafil in Migraine Without Aura. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sildenafil-migraine-without-aura
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →